A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia.

Trial Profile

A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jul 2010 Additional lead investigator (Badiah Yahya, MD) identified as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Actual initiation date (April 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top